Neil Parrott - Concepedia

Author

Neil Parrott

Roche (Switzerland)ORCID

Also Known As

N Parrott, N. Parrott, Neil J Parrott, Neil J. Parrott, Neil John Parrott, Neil Parrott, Neil J. Parrott

168

Publications

6.9K

Citations

H-Index

121

Concepts

All Affiliations

Roche (Switzerland)Merck & Co., Inc., Rahway, NJ, USA (United States)AstraZeneca (United Kingdom)Janssen (Belgium)University of Basel

About

Neil Parrott is an author at Roche (Switzerland) specializing in medicine, pharmacology, and pharmacokinetics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	30	48	2.9K
2	Health Sciences	8	8	472
3	Natural Sciences	6	6	249
4	Engineering	5	5	225
5	Public Health	4	4	224

Neil Parrott

Publications

4.6K

Citations

H-Index

Page 1

	Year	Citations
A Novel Strategy for Physiologically Based Predictions of Human Pharmacokinetics Hannah M. Jones, Neil Parrott, Karin Jorga, Clinical Pharmacokinetics Physiologically Based PharmacokineticsPharmacokinetic ModelingPharmacological StudyHuman PharmacokineticsMedicine	2006	344
Prediction of intestinal absorption: comparative assessment of gastroplus™ and idea™ Neil Parrott, Thierry Lavé European Journal of Pharmaceutical Sciences NutritionFunctional Gastrointestinal DisorderFood DigestionPhysiologyGastroenterology	2002	168
Predicting Pharmacokinetic Food Effects Using Biorelevant Solubility Media and Physiologically Based Modelling Hannah M. Jones, Neil Parrott, Gerd Ohlenbusch, Clinical Pharmacokinetics NutritionPhysiologically Based PharmacokineticsPharmacological StudyMedicinePhysiology	2006	147
A novel orally available small molecule that inhibits hepatitis B virus expression H. Mueller, Steffen Wildum, Souphalone Luangsay, Journal of Hepatology	2017	137
Applications of Physiologically Based Absorption Models in Drug Discovery and Development Neil Parrott, Thierry Lavé Molecular Pharmaceutics Pharmaceutical ResearchPhysiologically-based Pharmacokinetic ModelingPharmacological StudyBioanalysisAnalytical Chemistry	2008	121
CTEP: A Novel, Potent, Long-Acting, and Orally Bioavailable Metabotropic Glutamate Receptor 5 Inhibitor Lothar Lindemann, Georg Jaeschke, Aubin Michalon, Journal of Pharmacology and Experimental Therapeutics	2011	121
Physiologically‐Based Pharmacokinetic Modeling in Renal and Hepatic Impairment Populations: A Pharmaceutical Industry Perspective Tycho Heimbach, Yuan Chen, Jun Chen, Clinical Pharmacology & Therapeutics	2020	119
Challenges and opportunities with modelling and simulation in drug discovery and drug development Thierry Lavé, Neil Parrott, Hans Peter Grimm, Xenobiotica	2007	114
Development of a Physiologically Based Model for Oseltamivir and Simulation of Pharmacokinetics in Neonates and Infants Neil Parrott, Brian E. Davies, Gerhard Hoffmann, Clinical Pharmacokinetics Health SciencesPharmacodynamicsPharmacological StudyMedicinePhysiology	2011	113
Advancing Predictions of Tissue and Intracellular Drug Concentrations Using <i>In Vitro</i>, Imaging and Physiologically Based Pharmacokinetic Modeling Approaches Yingying Guo, Xiaoyan Chu, Neil Parrott, Clinical Pharmacology & Therapeutics EngineeringBiomedical EngineeringPharmacokinetic Modeling ApproachesPhysiologically-based Pharmacokinetic ModelingPharmacodynamic Modeling	2018	113

Page 1